191
Participants
Start Date
November 30, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
May 31, 2011
Abatacept
Solution, intravenous, monthly, short-term = 24 weeks (6 months)
Placebo
Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
Local Institution, Capital Federal
Local Institution, Rosario
Local Institution, Lillehammer
Local Institution, Santa Fe
Local Institution, Leuven
Local Institution, Fitzroy, Melbourne
Local Institution, Hasselt
Local Institution, Maroochydore
Local Institution, Cairns
Local Institution, Panorama
Local Institution, A Coruña
Altoona Center For Clinical Research, Duncansville
Rheumatic Disease Associates, Ltd., Willow Grove
Local Institution, Hamburg
Arthritis Clinic & Carolina Bone & Joint, Pa, Charlotte
Local Institution, Hildesheim
Sarasota Arthritis Research Center, Sarasota
Local Institution, Montpellier
Rheumatology Associates Of North Alabama, Huntsville
Local Institution, Chambray-lès-Tours
Local Institution, Reggio Emilia
Deaconess Hospital, Cincinnati
Justus Fiechtner, Md, Mph, Lansing
Midwest Arthritis Center, Kalamazoo
St. Paul Rheumatology P.A., Eagan
Local Institution, Lille
Local Institution, Frankfurt am Main
Health Research Of Oklahoma, Oklahoma City
Chase, Walter F., Austin
Local Institution, Napoli
Local Institution, Potenza
Boling Clinical Trials, Upland
Desert Medical Advances, Palm Desert
Stanford University School Of Medicine, Palo Alto
Seattle Rheumatology Associates, Seattle
Arthritis Northwest, Spokane
Joao Nascimento, Bridgeport
New England Research Associates, Llc, Trumbull
Clinical Pharmacology Study Group, Worcester
Local Institution, St. John's
Local Institution, Montreal
Local Institution, Québec
Local Institution, Trois-Rivières
Local Institution, Amsterdam
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY